The Long Run with Luke Timmerman
Timmerman Report
"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Episodes
Mentioned books
Feb 1, 2023 • 1h 1min
Ep128: Rick Berke on Building a Biotech Journalism Outlet to Last
Rick Berke, co-founder and executive editor of STAT, on building a biotech journalism outlet to last.
Jan 20, 2023 • 1h 10min
Ep127: Jeb Keiper on Computational Drug Discovery
Jeb Keiper, CEO of Nimbus Therapeutics, on computational drug discovery, an unusual business model, and an important new Tyk2 inhibitor for psoriasis and other forms of autoimmunity.
Jan 3, 2023 • 1h 12min
Ep126: DA Wallach on Becoming a Biotech VC
DA Wallach, founder and general partner of TIME Bioventures, on becoming a biotech venture investor.
Dec 19, 2022 • 1h 5min
Ep125: Barry Greene on a New Drug for Depression
Barry Greene, CEO of Cambridge, Mass.-based Sage Therapeutics, on plans to introduce a new type of treatment for depression and postpartum depression.
Nov 8, 2022 • 1h 10min
Ep124: Shehnaaz Suliman on Delivery of Genetic Medicines
Shehnaaz Suliman, CEO of ReCode Therapeutics, on lipid nanoparticle delivery of genetic medicines.
Oct 27, 2022 • 1h 15min
Ep123: Tariq Kassum on Single-Cell Analysis for Drug Discovery
Tariq Kassum, CEO of Cambridge, Mass.-based Celsius Therapeutics, on using single cell technology for drug discovery.
Oct 11, 2022 • 1h
Ep122: Aetna Wun Trombley on Extracellular Protein Degraders
Aetna Wun Trombley, CEO of Lycia Therapeutics, on extracellular protein degraders.
Sep 26, 2022 • 1h 4min
Ep121: Samantha Truex on Going Upstream Against Severe Asthma
Samantha Truex, CEO of Upstream Bio, on a new approach to treating severe asthma and other inflammatory diseases.
Sep 7, 2022 • 1h 4min
Ep120: Tim Lu on Gene Circuits for Cell Therapy
Tim Lu, CEO of Senti Biosciences, on developing gene circuits for cell therapy.
Aug 22, 2022 • 1h 3min
Ep119: Jo Viney on Discovering Treatments for Autoimmune Disease
Jo Viney, CEO of Seismic Therapeutic, on discovering new treatments for autoimmune disease.
